
# THE DEVASTATING IMPACT OF

## **CARDIAC AMYLOIDOSIS**



## PATIENT PERSPECTIVES FROM A US SURVEY<sup>7</sup>

### DIAGNOSIS

for cardiac amyloidosis patients is often a

LONG AND COMPLEX JOURNEY



of patients SAID THEIR **CONCERNS** about cardiac amyloidosis symptoms were **IGNORED BY OTHER** HCPs prior to diagnosis<sup>7</sup>



reported being **MISDIAGNOSED** with another condition prior to diagnosis<sup>7</sup>

On average, patients reported seeing



NA

**DOCTORS** for symptoms related to cardiac amyloidosis prior to a diagnosis<sup>7</sup>

### The PHYSICAL AND SOCIAL IMPACT

#### on cardiac amyloidosis patients is **SIGNIFICANT**



of patients agreed that due to their cardiac amyloidosis they often had to PUT THEIR LIFE ON PAUSE (eg, by avoiding things like)<sup>7</sup>:





More than 70%





of patients living with cardiac amyloidosis said they generally

NEVER FEEL WELL<sup>7</sup>

of patients said cardiac amyloidosis negatively impacts their ROMANTIC RELATIONSHIPS/INTIMACY a lot or a great deal<sup>7</sup>





of cardiac amyloidosis on patients

#### **CANNOT BE OVERLOOKED**



Common words patients used to **DESCRIBE THEIR FEELINGS** toward living with cardiac amyloidosis<sup>7</sup>



of patients reported that **NO ONE UNDERSTANDS** the **NEGATIVE IMPACT** cardiac amyloidosis has on their everyday life<sup>7</sup>



of patients were either VERY or EXTREMELY **CONCERNED** about their current health<sup>7</sup>

# Visit yourheartsmessage.ie and speak to your doctor for more information about ATTR-CM

- 1. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleveland Clinic Journal of Medicine. 2017;84(12 suppl 3):12-26. doi:10.3949/ccjm.84.s3.02.
- 2. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-2412. doi:10.1161/circulationaha.116.021612.
- 3. Sipe JD, Benson MD, Buxbauym JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification. Amyloid. 2016;23(4): 209-213.
- 4. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357-1377.
- 5. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. Current Opinion in Cardiology. 2018:1. doi:10.1097/hco.00000000000547.
- 6. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Ciruclation. 2012;126(10):1286-1300.
- 7. Pfizer Data on File. Survey Conducted by Harris Poll, 2018.



This survey was conducted online by Harris Poll on behalf of Pfizer from Nov 9-Dec 10, 2018 among 335 US adults aged 18+ who have been diagnosed by a healthcare professional with heart failure or cardiac amyloidosis, including 75 cardiac amyloidosis patients.